Background. Contrast-induced acute kidney injury (CI-AKI) increases the likelihood of patient morbidity and mortality following coronary procedures. Volume supplement with saline is the standard treatment to prevent CI-AKI. Additional antioxidant prophylaxis has often yielded conflicting results. The present study was conducted to examine the role of novel application vitamin E (tocopherol) in preventing CI-AKI. Methods. This prospective, double-blind, randomized and placebo-controlled trial was carried out in 305 patients with chronic kidney disease (CKD) undergoing coronary procedures. All patients were randomly assigned to prophylaxis administration with 0.9% saline infusions plus daily oral medication comprised of either (i) placebo (n = 101), (ii) α-tocopherol (n = 102) or (iii) γ-tocopherol (n = 102) starting 5 days before and ending 2 days after coronary procedures. The CI-AKI risk score of each patient was calculated. All coronary procedures were performed using a low-osmolar, non-ionic contrast agent. Results. CI-AKI developed in 14.9% in the placebo group, 4.9% in the α-tocopherol group (P = 0.02 versus the placebo group) and 5.9% in the γ-tocopherol group (P = 0.04 versus the placebo group). In patients with diabetes, hypertension, anaemia, aged over 55 years, male gender or with contrast agent dosages >120 mL, α-tocopherol showed a larger effect than γ-tocopherol when compared with the placebo group (P < 0.05). Conclusions. Prophylaxis administration with oral α-or γ-tocopherol in combination with 0.9% saline is effective in protecting against CI-AKI in CKD patients undergoing elective coronary procedures.
Introduction
Contrast-induced acute kidney injury (CI-AKI) is the most common iatrogenic cause of new acute kidney injury (AKI) after intravenous contrast media administration, with a published incidence ranging from 1 to 25% [1] [2] [3] [4] . In general, impairment of renal function [increase in serum creatinine (SCr) >25% or 0.5 mg/dL] in CI-AKI occurs within 3 days after intravenous contrast media administration, while the peak of SCr is observed at 3-5 days and returns to the baseline value within 1-3 weeks [5, 6] . The incidence of CI-AKI is low (1-2%) in patients with normal renal function [1] but increases as high as 25% in high-risk patients, especially with chronic kidney disease (CKD) or diabetes mellitus [4] . CI-AKI requiring dialysis developed in ∼3% of patients after percutaneous coronary intervention [7] and 4% of patients with underlying CKD with coronary procedures [8] . CI-AKI, particularly in CKD patients, contributes to extended hospitalizations and increases long-term morbidity and mortality [9] . Typically, development of CI-AKI is due to the ability of contrast agents to induce renal vasoconstriction followed by hypoxia of the renal medulla. Hypoxia can promote further ischaemic renal injury by the increase in oxygen free-radicals through oxidative stress [10] . Organ injury occurs when tissue hypoperfusion generates reactive oxygen species (ROS) that exceed the patient's antioxidant reserves [11] . Contrast agents also result in direct tubular toxicity [11, 12] .
Several strategies to prevent CI-AKI have been tested in animal models and clinical trials. Hydration with isotonic saline and use of iso-osmolar contrast agents have provided more consistent positive results in the prevention of CI-AKI [13, 14] . Other agents, e.g. dopamine, captopril, theophylline, atrial natriuretic peptide and calcium channel blockers, were ineffective [15, 16] . Recent studies concerning antioxidants N-acetylcysteine (NAC) and ascorbic acid (vitamin C) as protective remedies against CI-AKI have yielded conflicting results [17] [18] [19] with a substantial proportion of patients still at risk to develop CI-AKI.
Vitamin E is a term used for eight naturally occurring compounds including α (alpha), β (beta), γ (gamma) and δ (delta) derivatives of tocopherol and tocotrienol. Differences in biological activity cause discrepancies in antioxidant and anti-inflammatory properties of each tocopherol. α-Tocopherol is the most active antioxidative substance [20] , while γ-tocopherol has higher antiinflammatory potency than α-tocopherol [21] . The antioxidative property of vitamin E has been demonstrated in many animal model studies; for example, in cisplatininduced AKI and ischaemic-reperfusion injury [22, 23] . Some forms of vitamin E have been proposed for the prevention or treatment of several health problems, particularly arteriosclerotic heart disease and cancer [24, 25] , primarily due to their antioxidant and anti-inflammatory properties [21, 26, 27] . It is postulated that tocopherol protects the cell membrane from lipid peroxidation and thereby acts as membrane stabilizers [28] . The present prospective, randomized, placebo-controlled trial was conducted to evaluate the effects of orally administered α-and γ-tocopherol during standard intravenous isotonic saline hydration on the biochemical markers of renal function, and on the clinical development of CI-AKI in CKD patients undergoing coronary procedure.
Materials and methods

Patient population
Patients with CKD who underwent clinically driven, elective coronary angiography and/or intervention at Thammasat Chalerm Prakiat Hospital during the period from January 2008 to December 2010 were included in this study. Approval was obtained from the Ethics Committee of the Faculty of Medicine, Thammasat University. All patients provided written, informed consent to participate in the study. Patients with baseline estimated glomerular filtration rate (eGFR) levels ≤60 mL/min, as measured in their most recent sample, and at least two measurements for ≥3 months prior to the beginning of the protocol, were included in the study. However, patients with AKI, CKD Stage 5 or unstable renal function (as evidenced by a change in SCr of ≥0.5 mg/dL, or ≥25%, within 14 days prior to the study) were excluded from further participation. Subjects were also excluded if they had a known allergy to any of the contrast agents, were receiving mechanical ventilation or suffered from congestive heart failure, cardiogenic shock or emergent angiography. Moreover, those receiving NAC, mannitol, diuretics, theophylline, dopamine, ascorbic acid or contrast agents within 14 days before study commencement were not included, as were those who used α-or γ-tocopherol supplements on a daily basis during the week prior to the study.
Study protocol
The study was designed as a prospective, randomized, double-blind, placebo-controlled trial. After enrolment, the patients were randomly assigned to receive one of the following oral regimens: (i) α-tocopherol (350 mg/day), (ii) γ-tocopherol (300 mg/day) or (iii) a placebo (350 mg/ day). In each group, the prescribed regimen was initiated 5 days prior to the coronary procedure and continued for a further 2 days post-procedure. Flavoured, yellow to brown-coloured α-and γ-tocopherol capsules were purchased from Pharma-Nord, Thailand, and NOW Foods, USA. Identical capsules were used for the placebo. The patients had to return the emptied packaging at the end of the study to prove compliance. All subjects received 0.9% saline infusion at a rate of 1 mL/ kg/h for 12 h before and 12 h after elective coronary procedures. Variation in the hydration rates was allowed for adjustments according to the clinical heart failure of an individual patient. Hospital procedures mandated accurate hourly recording of all in-hospital volume inputs for patients who underwent elective coronary interventions. All patients were encouraged to drink if they were thirsty.
Coronary intervention was performed by the standard protocol via either the radial or femoral approach by the attending interventional cardiologist. When therapeutic coronary interventions were required, the procedure was performed immediately following angiography and according to the recommendations. All procedures were performed using a low-osmolar, nonionic contrast medium agent (Iopromide, Schering AG, Germany).
Venous blood samples were collected for the measurement of complete blood count, serum blood urea nitrogen (BUN) and SCr baseline levels 12-24 h prior to intervention and again 48 h after the procedure. eGFR was calculated using the Modification of Diet in Renal Disease Formula, where eGFR = 175 × plasma creatinine -1.154 × age -0.203 (× 0.742 if female; × 1.21 if African American). All measurements were performed using standard methods in a single, hospital-based laboratory.
The risk score for predicting CI-AKI development was calculated according to Mehran et al. [29] . Risk score assessment was evaluated by definition of clinical and cut-off point of laboratory investigation. Specific clinical and laboratory data were obtained from the hospital charts that were reviewed by research investigators who were blinded in our study.
Study end points
The primary end point of this study was the development of CI-AKI, defined as an absolute increase in SCr of ≥0.5 mg/dL or a relative increase of ≥25% in SCr 48 h after the coronary procedure, when compared with baseline measurements. Secondary end points included changes in SCr and eGFR 48 h after the coronary procedure, when compared with baseline levels, but also included the side effects of study medication, and the requirement for dialysis. AKI requiring dialysis was defined as a decrease in renal function and essentially the need for acute haemodialysis or peritoneal dialysis within the first week after coronary procedure.
Statistical methods
Treatment assignment among the three groups was determined by randomization in a 1:1:1 ratio. To ensure that patients were randomized in equal numbers between the three treatment groups, making the combination of three groups in a randomization block was operated. The sample size was selected to demonstrate a reduction in the primary end point of CI-AKI from 15% in the saline plus placebo group [29] to 4% in the saline plus α-tocopherol group and/or saline plus γ-tocopherol group [30, 31] . With the use of a two-sided χ 2 test with a significance level of 0.05, the number of subjects in each group was 102 and a total of 306 randomized patients gave the study 90% power.
All data were expressed as mean ± SD for continuous variables and as percentages for discrete variables. Demographic clinical outcome characteristics of the study groups were analysed by the analysis of variance test for continuous measurements and the χ 2 test statistic for categorical measurements. For categorical variables with expected values <5, the Fisher exact test was used. The χ 2 test was performed to compare the three treatment group for the primary end point of CI-AKI. The influence of contrast agents on the change in SCr, and eGFR 48 h after the coronary procedure in each treatment group was evaluated by means of univariate analyses of variance. Differences in SCr, and eGFR before (baseline) and 48 h after the coronary procedure were analysed with the paired t-test. The effects of other significant covariates on the development of CI-AKI in the treatment groups such as diabetes mellitus, hypertension, contrast agent dosage, age, baseline eGFR, anaemia and gender were evaluated by means of the χ 2 test. Secondary analyses included comparison of the absolute change in SCr and eGFR among the study groups and of the mean baseline and follow-up SCr and eGFR within each group. All statistical tests were two-sided. Statistical analyses were performed with SPSS software (version 15.0, SPSS, Inc.) and significance was assigned when P-values of <0.05 were obtained.
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Results
A total of 1839 patients referred for coronary angiography and/or intervention were screened between January 2008 and December 2010 ( Figure 1 ). Of these patients, 342 patients met the inclusion criteria based on a baseline eGFR <60 mL/min and were enrolled in this study. Thirty-three patients were excluded from the study because 26 patients refused to participate, five patients suffered from congestive heart failure and two patients developed AKI. Finally, 309 CKD patients were randomized 1;1:1 and distributed into three treatment groups: (i) α-tocopherol, (ii) γ-tocopherol and (iii) placebo ( Figure 1 ). Four patients did not complete the study because they did not undergo SCr evaluation 48 h after contrast exposure. Consequently, 305 patients were analysed, 101 patients in the placebo group, 102 patients in the α-tocopherol group and 102 patients in the γ-tocopherol group (Figure 1 ). Their baseline clinical and biochemical characteristics are shown in Tables 1 and 2 . Statistically significant differences between the groups were not found for clinical characteristics, especially underlying diseases and α-and γ-tocopherol prevent CI-AKI 339 concomitant medications. The volume of the administered contrast agent was comparable in all groups (placebo, 134 ± 69 mL; α-tocopherol, 134 ± 73 mL and γ-tocopherol, 137 ± 75 mL; P = 0.94) as was the volume of saline infusion (placebo, 1520 ± 370 mL; α-tocopherol, 1353 ± 320 mL and γ-tocopherol, 1498 ± 300 mL; P = 0.48). An identical CI-AKI risk score of 8 ± 3 was noted in all groups (Table 1) . High CI-AKI risk scores ≥11 were observed in 19 patients each (19%) in the placebo and α-tocopherol groups and in 24 patients (24%) in the γ-tocopherol group (P = 0.75). Moreover, baseline SCr and eGFR levels were not statistically different between all groups (Table 2 ).
Primary end point: incidence of CI-AKI
CI-AKI developed in 14.9% of patients in the placebo group but only in 4.9 and 5.9% in the α-and γ-tocopherol groups, respectively ( Table 3 ). The corresponding odds ratios (ORs) in comparison with the placebo group were 0.29 [95% confidence interval (CI) 0.1-0.85; P = 0.02] for the α-tocopherol group and 0.36 (95% CI 0.13-0.97; P = 0.04) for the γ-tocopherol group (Table 4) . When, newer criteria of AKI from the Kidney Disease Improving Global Outcome guideline 2012 were applied for diagnosis of CI-AKI, the incidence of CI-AKI was 23.8% of the patients in the placebo group but only in 12.7 and 15.7% in the α-and γ-tocopherol groups, respectively ( Table 3) . The corresponding ORs in comparison with the placebo group were 0.46 (95% CI 0.22-0.98; P = 0.04) for the α-tocopherol group and 0.6 (95% CI 0.3-1.2; P = 0.16) for the γ-tocopherol group. To evaluate the CI-AKI frequency in relation to different risk scores, all patients were additionally categorized into four groups with risk scores of (A) 1-5, (B) 6-10, (C) 11-15 and (D) 16-20. In the placebo group, CI-AKI developed in (A) 3.7, (B) 14.54, (C) 31.25 and (D) 33.33% of the patients, respectively. The incidence rate of CI-AKI was (A) 0, (B) 3.33 (P < 0.05; compared with the placebo group), (C) 12.5, and (D) 33.33%, respectively, in the α-tocopherol group and (A) 0, (B) 5, (C) 15 and (D) 25%, respectively, in the γ-tocopherol group (Figure 2) .
In a subgroup analysis, the effectiveness of the three treatment regimens was evaluated based on the following seven variables: diabetes mellitus, hypertension, volume of contrast media >120 mL, age >55 years, gender, anaemia and risk score <10. Statistically, the rate of CI-AKI in the α-tocopherol group was significantly lower in all variable subgroups (P < 0.05) with the exception of variable gender: female when compared with the placebo group (Table 4 ). In contrast, the incidence of CI-AKI in the γ-tocopherol group was lower only in the subgroup of patients with the risk score <10 (P < 0.05) when compared with the placebo group (Table 4) .
Secondary end point: changes in SCr and eGFR
At 48 h following coronary procedures, SCr and eGFR were measured in all 305 patients. At baseline, the mean SCr concentration was not statistically different among the three treatment groups (P = 0.11), while it was significantly increased 48 h post-coronary procedure in the placebo group from 1.63 ± 0.53 to 1.77 ± 0.85 mg/dL (P = 0.03, Table 2 ). In contrast, the mean SCr concentration in the α-and γ-tocopherol groups was only slightly changed from 1.58 ± 0.48 to 1.59 ± 0.6 mg/dL (P = 0.74) and from 1.48 ± 0.48 to 1.5 ± 0.69 mg/dL (P = 0.64), respectively ( Figure 3 and Table 2 ).
All groups showed no statistically significant change in eGFR 48 h after the coronary procedure compared with the baseline level. In the placebo group, the mean eGFR was 43 ± 13 mL/min at baseline and 43 ± 17 mL/min 48 h later (P = 0.93), while in the α-and γ-tocopherol groups, the mean eGFR was only slightly different between the two time-points (45 ± 13 mL/min at baseline to 47 ± 16 mL/min; P = 0.4 and 46 ± 15 mL/min at baseline to 49 ± 19 mL/min; P = 0.26, respectively) ( Table 2) .
None of the patients who developed CI-AKI required renal replacement therapy. Few patients in the α-and γ-tocopherol groups experienced minor side effects, including nausea, vomiting and abdominal discomfort on the initial day of drug administration.
Discussion
To our knowledge, this present study is the first clinical trial of the antioxidant vitamin E in its forms of α-and γ-tocopherol in the prevention of CI-AKI and the results demonstrate a remarkable effect of these two compounds. Statistical analysis of the data obtained through the described prospective, double-blind, randomized and placebo-controlled trials strongly suggests that prophylactic oral administration of α-and γ-tocopherol reduces the incidence of CI-AKI compared with a placebo control Each subgroup analysis shows benefit of α-and γ-tocopherol therapy in different patient subsets. eGFR, estimated glomerular filtration rate; CI-AKI, contrast-induced acute kidney injury; OR, odds ratio. Fig. 2 . Incidence of CI-AKI derived from interval of total risk score. n = 68 risk score 1-5, n = 175 risk score 6-10, n = 52 risk score 11-15 and n = 10 risk score 16-20. Solid bars = placebo group; open bars = α-tocopherol group; grey bars = γ-tocopherol group. *P < 0.05 compared with the placebo group.
α-and γ-tocopherol prevent CI-AKIwhen used in conjunction with 0.9% saline hydration in CKD patients undergoing coronary procedures. Interestingly, the greatest prophylactic effect of α-tocopherol was observed in the subgroups of patients with diabetes mellitus, hypertension, receiving contrast agent dosages >120 mL, patients aged 55 years or older, male gender, anaemic patients and CI-AKI risk score <10. Investigation of the pathogenesis of CI-AKI has revealed that the nephropathy following contrast media administration is caused by a combination of regional hypoxia, generation of ROS and direct cytotoxic effects on the renal epithelial cells [32] . The contrast-induced cytotoxicity is probably caused by iodine and oxidative stress, leading to primary cell membrane of endothelial and tubular epithelial cell damage causing apoptosis and cell death [33] . Hydration with isotonic saline lead to improve renal haemodynamics, resulting in attenuated vasoconstriction effect and increased renal blood flow and urine output [13] . Therefore, all patients in this study received isotonic saline as the standard prevention treatment of CI-AKI. Interestingly, many studies demonstrated the imbalance between pro-oxidant and antioxidant levels in CKD patients [34] . Thus, CKD patients had higher levels of plasma oxidative markers and decreased antioxidative activities which were correlated with the level of renal dysfunction [35, 36] . These observations suggest that administration of antioxidants in CKD patients possibly prevents CI-AKI by decreasing ROS. Therefore, attempts were made to develop CI-AKI prophylaxis protocols for CKD patients by using antioxidants in combination with standard therapy. The antioxidant NAC has been tested for CI-AKI prevention, but there are conflicting reports on its effectiveness [2, 37] . Moreover, recent clinical trials investigated the use of ascorbic acid (vitamin C) in the prevention of CI-AKI, but the results were inconclusive and required larger clinical trials for confirmation [18, 19, 38] .
Our study reveals the potential of vitamin E in the prevention of CI-AKI. Prior in vivo and in vitro studies had already demonstrated the antioxidative and anti-inflammatory properties of α-and γ-tocopherol [27, 39] and in a pilot study, Tasanarong et al. [40] demonstrated that vitamin E could prevent CI-AKI in CKD patients undergoing elective coronary procedure. In the present study, the Mehan risk score [29] was used to estimate the risk of CI-AKI development. Most patients enrolled in this clinical trial had a moderate-to-high risk score with a mean risk score of 8 ± 3, and 14% expected risk of CI-AKI and 0.12% risk of dialysis. The observed incidence rate of CI-AKI in the placebo group of our study (14.9%) was comparable with the previously reported CI-AKI rate in patients with moderate risk score [29] , while the α-and γ-tocopherol administration caused significantly lower incidence rates (4.9 and 5.9%, respectively) in CKD patients following coronary procedures. This result is consistent with the data of our pilot study [40] and confirms the beneficial application of vitamin E in the prevention of CI-AKI. Moreover, the incidence of CI-AKI in high risk score patients was 31.25% in the placebo group, while the α-and γ-tocopherol administration reduced the incidence rates of CI-AKI (12.5 and 15%, respectively) in these patients. However, the advantage of α-and γ-tocopherol administration in high risk score patients did not demonstrate any statistical significance due to the low number of patients with high risk score in the present study and/or these patients might need higher dose of α-and γ-tocopherol to prevent CI-AKI. α-Tocopherol seems to have a larger effect than γ-tocopherol in preventing CI-AKI in the subgroups of patients with diabetes, hypertension, receiving contrast agent >120 mL, age >55 years, male gender, anaemia and medium-to-high CI-AKI risk score. Vitamin E was discovered in 1922 and its active substance was isolated in 1936 called 'tocopherol' [41] . Vitamin E is a major lipidsoluble antioxidant protecting against peroxidative damage of the cell membrane and the prefixes α, β, γ and δ are used to distinguish the family and activity of the compound [42, 43] . Differences in the antioxidative activity depend on the relative hydrogen donating ability of the different tocopherols. In vivo and in vitro studies demonstrated that α-tocopherol is the most efficient antioxidative substance, especially when compared with γ-tocopherol [20] .
The antioxidative effect of tocopherol (vitamin E) is different from NAC and ascorbic acid (vitamin C). Vitamin E is a lipid-soluble, non-enzymatic antioxidant which protects tissues and cells from free radical attack by acting as cell membrane stabilizer and maintaining cell bioactivity [28] . Vitamin C, present as ascorbate, is a water-soluble, non-enzymatic antioxidant and is considered the most important antioxidant in extracellular fluid. It can trap peroxyl radicals in the aqueous phase before they can initiate lipid peroxidation at the cell membrane [44] . The effect of NAC may be direct through its own antioxidative property or indirect through stimulation of glutathione synthesis. Glutathione itself is a watersoluble, non-enzymatic antioxidant. NAC administration has been demonstrated to increase intracellular GSH level in the rat kidney, but this effect could not be demonstrated in humans [17] . The different site and mode of actions of the indicated antioxidants certainly play a role in their various benefits to human health and it appears that vitamin E is the most suitable agent to prevent CI-AKI.
Limitations
First, the present study has only been conducted in a single hospital. We have to extend this protocol to include other localities and perform a multi-hospital study. Secondly, the results of our study are not representative for the incidence of CI-AKI in high and very high-risk patients (score ≥16) because their number was insufficient and we need more data to statistically substantiate the effects of vitamin E in these patients. Thirdly, the patients were only observed for 48 h while in the natural course of CI-AKI, the SCr level will peak 2-3 days after contrast medium administration and return to its normal value within 2 weeks [12] . Therefore, the present study may miss the peak SCr levels in some patients. Fourthly, we did not test vitamin E in parallel with NAC or other antioxidants. However, we did have a placebo control. Fifthly, we were not able to include a recently reported novel biomarker [45] to detect early AKI due to the biomarker being reported after the initiation of this study.
In conclusion, both α-and γ-tocopherol are safe, welltolerated, inexpensive and available as an alternative oral medication to prevent CI-AKI in CKD patients undergoing coronary procedures. α-Tocopherol seems to be superior to γ-tocopherol in preventing CI-AKI in patients with one or more of the following characteristics: diabetes, hypertension, receiving contrast agent >120 mL, age >55 years, male gender, anaemia and medium-to-high CI-AKI risk score.
